Why this article exists
BPC-157 is the peptide dental patients ask about most, usually after an extraction, an implant, or periodontal surgery, and usually because something online said it "heals everything." A practice needs a better answer than a shrug, and a more honest one than the internet's. So we searched PubMed and ClinicalTrials.gov for every dental or oral BPC-157 study, verified each one by PubMed ID, and read the abstract to confirm it says what we say it says.
The whole dental literature fits in this article.
Educational only. PeptIQ.io does not sell, source, or dispense peptides. Nothing here is a treatment recommendation and no dosing appears.
Study 1: rat periodontitis (2009)
Keremi B et al., Journal of Physiology and Pharmacology, 2009 (Semmelweis University, Budapest, with Sikiric's group in Zagreb).
- Type: animal, rat ligature-induced periodontitis.
- Measured: gingival inflammation and alveolar bone resorption.
- Reported: BPC-157 was associated with reduced gingival inflammation and alveolar bone loss in the model.
- What it is not: a human study, a periodontal treatment, or evidence about any patient outcome. It is the kind of proof-of-concept animal work that normally precedes a trial. Seventeen years later, there is no trial.
Study 2: rat alcohol injury including the tongue (2018)
Becejac T et al., Journal of Physiology and Pharmacology, 2018.
- Type: animal, rats given strong alcohol that injured the tongue and upper GI tract.
- Measured: lesion resolution across the injured tissues.
- Reported: the authors described reversal of the lesions, including those on the tongue.
- What it is not: an oral-disease study. The design is about gastric cytoprotection; the tongue was one of several injured sites. It is in this list because it is the only other oral tissue in the BPC-157 literature.
Study 3: three human cases of nerve injury (2026)
Froum S et al., Frontiers in Oral Health, 2026 (Stony Brook University School of Dental Medicine).
- Type: human case series, three patients, uncontrolled.
- Setting: inferior alveolar nerve injury, treated with a multimodal regimen that included BPC-157, TB-500 and ARA-290.
- Reported: the authors describe the clinical course and state plainly that causality cannot be established and that the peptides remain investigational.
- What it is not: a trial, a controlled comparison, or evidence that any component of the regimen did anything. It is the first human dental literature on BPC-157, and the authors themselves frame it as hypothesis-generating.
What we looked for and did not find
- No human trial of BPC-157 for any dental, periodontal, extraction, implant, or oral-mucosal outcome, on PubMed or ClinicalTrials.gov. The registered BPC-157 trials are musculoskeletal, pharmacokinetic, or healthy-volunteer studies.
- No extraction-socket study, animal or human. The "BPC-157 after tooth extraction" idea has no study behind it at all.
- No implant or osseointegration study.
- One rat incisional-pain study sometimes cited in dental contexts (Jung 2022) used a hind-paw incision, not an oral wound, so it does not belong on this list.
In our evidence tables that makes BPC-157 animal only for periodontal and oral-mucosal uses, and human, limited for post-surgical healing solely because of the three-case report, with the caveat printed next to it.
The FDA status, read on October 16, 2026
- Not FDA-approved for anything.
- Listed on FDA's compounding safety-risk page under "bulk drug substances nominated but withdrawn," where FDA writes that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration" and that the agency "has identified no, or only limited, safety-related information for the proposed routes of administration."
- Not in 503A Category 1, 2, or 3 on the current category list (updated May 14, 2026). That matters because FDA's interim enforcement policy applies only to substances that appear in Category 1.
- On the agenda of the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting. FDA's own presentation proposed that BPC-157 not be included on the 503A bulks list. The committee's vote is not posted on any FDA page; secondary sources report a split vote in favor, which we do not cite as authority.
The dental evidence guide quotes each of these sources in full.
